Central serous papillopathy by optic nerve head drusen
Ana Marina Suelves1, Ester Francés-Muñoz1, Roberto Gallego-Pinazo1, Diamar Pardo-Lopez1, Jose Luis Mullor2, Jose Fernando Arevalo3, Manuel Díaz-Llopis1,4,5
1Department of Ophthalmology, La Fe University Hospital, Valencia, Spain; 2Instituto de Investigación Sanitaria, Fundación para la investigación, La Fe Hospital, Valencia, Spain; 3Retina and vitreous service, Clínica Oftalmológica Centro Caracas, Caracas DC, Venezuela; 4Department of Ophthalmology, University of Medicine, Valencia, Spain; 5CIBERER, The Biomedical Network Research Centre on Rare Diseases, Valencia, Spain
Abstract: We report a 38-year-old man with a complaint of blurred vision in his right eye for the previous 5 days. He had bilateral optic disc drusen. Fluorescein angiography revealed multiple hyperfluorescent foci within temporal optic discs and temporal inferior arcade in late phase. Optical coherence tomography showed bilateral peripapillary serous detachment as well as right macular detachment. This is the first reported case of a concurrent peripapillary and macular detachment in a patient with central serous papillopathy by optic disc drusen. Central serous papillopathy is an atypical form of central serous chorioretinopathy that should be considered as a potential cause of acute loss of vision in patients with optic nerve head drusen.
Keywords: central serous papillopathy, peripapillary central serous chorioretinopathy, optic nerve head drusen, peripapillary subretinal fluid
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.